Skip to main content

Table 1 Clinical-pathological features of Cohort I pLGG patients

From: MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression

Cohort I pLGG patients

Sample code

Age (years)

Gender

Site of onset

Histology

Type of resection

Progression

Progression Free Survival (years)

Overall Survival (years)

Mutational status of BRAF

Profiling (P) / ddPCR (d)

22233

5

M

H Supra

DNET

NTR

WITH

2

9

NA

P + d

OPBG13P

4

F

H Supra

DNET

NTR

WITH

4.4

8

WT

P

16526

13

F

H Supra

GG

NTR

WITH

7

8

V600E

P + d

19683

12

F

H Supra

GG

NTR

WITH

2

9

WT*

P + d

22457

9

M

H Supra

GG

NTR

WITH

7

10

V600E

P + d

11364

12

M

H Supra

GG

NTR

WITH

5

10

WT*

P + d

25,595

4

M

H Supra

PA

NTR

WITH

1

NA

WT*

P + d

11720

2

M

H Supra

PA

NTR

WITH

2

NA

WT*

P + d

8380

16

F

H Supra

PA

NTR

WITH

2

12

WT*

P + d

21617

6

M

H Supra

PA

NTR

WITH

5

13

WT*

P + d

256 13

3.6

M

Md Supra

PA

NTR

WITH

0.58

7

K15B9

P + d

OPBG45C

7

F

Md Supra

GG

Biopsy

WITH

4

7

WT

P + d

OPBG62P

3.7

M

Md Supra

GG

Biopsy

WITH

0.5

5

WT

P + d

OPBG51S

6.8

F

Md Supra

PA

NTR

WITH

0.66

5

K16B11

P + d

119637 FF

6

M

Md Supra

PA

NTR

WITH

1.58

14

K16B9

P + d

179435 FF

6

M

Md Supra

PA

NTR

WITH

4.25

17

K16B9

P + d

177408 FF

6

M

Md Supra

PA

NTR

WITH

0.75

12

WT*

P + d

123965 FF

8

F

Md Supra

PA

NTR

WITH

2.08

16

K15B9

P + d

89636 FF

2

F

Md Supra

PA

NTR

WITH

9.33

25

WT*

P

117945 FF

0.91

M

Md Supra

PA

NTR

WITH

1.83

17

WT

P + d

OPBG135F

7

M

Md Supra

PA

Biopsy

WITH

0.5

1.66

WT*

d

1651

13

M

H Supra

AG

NTR

W/O

8

8

WT*

P + d

OPBG54M

8

F

H Supra

DNET

NTR

W/O

5

5

WT

P + d

OPBG74M

5

F

H Supra

DNET

NTR

W/O

2.16

2.16

WT*

P + d

OPBG112I

14

F

H Supra

GG

NTR

W/O

0.33

0.33

V600E

d

OPBG94C

5.3

F

Md Supra

PA

NTR

W/O

1

1

WT*

P + d

OPBG43D

3

M

Md Supra

PA

NTR

W/O

3.75

3.75

K16B9

P + d

OPBG58SP

5

M

Md Supra

PA

NTR

W/O

3

3

WT

P + d

172524 FF

14

M

Md Supra

PA

NTR

W/O

12

12

WT*

P + d

45723 FF

16

F

Md Supra

PA

NTR

W/O

17

17

V600E

P + d

75683 FF

7

M

Md Supra

PA

NTR

W/O

16

16

WT*

P + d

OPBG99D

10

M

Md Supra

GNT

NTR

W/O

0.91

0.91

V600E

d

OPBG115C

7

F

Md Supra

PA

Biopsy

W/O

0.33

0.33

K15B9

d

OPBG117C

10

F

Md Supra

GG

Biopsy

W/O

0.5

0.5

WT

d

  1. H Hemispheric, M Midline, DNET Dysembryoplastic Neuropepithelial Tumor, GG Ganglioglioma, GT Glioneuronal Tumor, PA Pilocytic Astrocytoma, AG Angiocentric Glioma, NTR Near Total Resection, WITH With progression, W/O Without progression, CR Complete remission, DoD Dead of Disease, SD Stable Disease, PR Partial Remission, NA Not applicable, ND Not detected. BRAF screening was limited to the V600E point mutation and three fusion genes [KIAA1549-BRAF exon 16-exon 9 (K16B9), KIAA1549-BRAF exon 16-exon 11 (K16B11), KIAA1549-BRAF exon 15-exon 9 (K15B9)]. WT* = Not screened for BRAF K15B9